By InvitationNot Applicable

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

United States60 participantsStarted 2021-07-01

Plain-language summary

A postoperative autologous blood patch (ABP) intervention trial for patients who underwent lung resection for cancer to examine its effectiveness in preventing a prolonged air leak. AIM 1: To determine the safety and efficacy of autologous blood patch (ABP) as a means to reduce the rate of prolonged air leak (PAL) after lung cancer resection AIM 2: To prospectively examine variation in morbidity and quality of life between patients with and without a PAL

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer * Patients that have reviewed and signed the Informed Consent Form, had an opportunity to ask questions, and consent to have their de-identified data included in the study * Patients who have an air leak on the morning of postoperative Day 3 * Age ≥18 years old Exclusion Criteria: * Patients who undergo pneumonectomy, sleeve lobectomy, chest wall or diaphragm resection, or bilateral procedures. * Age \< 18 years old * Women who are pregnant

What they're measuring

Prolonged Air Leak >5 days

Timeframe: Within 30 Days

Hospital Length of Stay

Timeframe: Within 30 Days

Readmission within 30 days

Timeframe: Within 30 Days

In hospital mortality

Timeframe: Within 30 Days

30-day Mortality

Timeframe: Within 30 Days

Trial details

NCT IDNCT04954625

SponsorRush University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Lung Cancer trials